Shares of Cara Therapeutics Inc. (CARA) are rising above 15% in pre-market today, following the company's announcement of positive results from global KALM-2 pivotal phase 3 trial of KORSUVATM injection in Hemodialysis patients with Pruritus.
from RTT - Before the Bell https://ift.tt/2zjTHTo
via IFTTT
No comments:
Post a Comment